This research provides strong evidence for the efficacy of subcutaneous injection of MSTN-ASO (KMM001) as a novel, targeted, and MSTN gene-specific approach in mitigating CKD-induced muscle-wasting conditions. This evidence concerns the gene MSTN and chronic kidney disease.